BioStock: Top oncologist underscores BioInvent’s potential for “Immunotherapy 2.0”
BioInvent recently announced promising clinical data for its lead cancer immunotherapy candidates, BI-1808 and BI-1206. The company hosted a Key Opinion Leader webinar to explain the results in detail, featuring insights from internationally recognized oncologist Dr Alexander Eggermont. According to Dr Eggermont, BioInvent’s candidates hold great promise for the future of immuno-oncology.
Read the article at biostock.se:
Top oncologist underscores BioInvent’s potential for “Immunotherapy 2.0” - BioStock
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/